low - Clinical trial timelines and regulatory processes are largely insulated from economic cycles. However, capital markets access for financing is highly sensitive to risk appetite and biotech sector sentiment. Hospital capital budgets for new technologies can be affected during severe recessions, potentially impacting post-approval adoption rates.

High sensitivity through multiple channels: (1) Rising rates compress biotech valuations as future cash flows are discounted more heavily - particularly acute for pre-revenue companies with 5+ year monetization timelines. (2) Higher rates increase cost of capital for future financings and reduce attractiveness of dilutive equity raises. (3) Rates affect institutional investor allocation to high-risk growth assets. With negative cash flow and financing needs, rising rate environment is materially negative for valuation multiples.

growth - High-risk, high-reward biotech investors and specialized healthcare funds willing to accept binary outcomes. Attracts momentum traders around clinical catalysts and regulatory milestones. Not suitable for value or income investors given negative cash flow, no dividends, and speculative nature. Requires long time horizon (3-5 years minimum) and tolerance for 50%+ drawdowns.